Hoppa till innehållet

Redeye: Alzinova Q4 – With wind in the sails

Redeye leaves a comment on the Q4 report published by Alzinova earlier today. Overall, the report did not include any major surprises. Following the positive results from the phase Ib study with ALZ-101, the main focus ahead will be to achieve a licensing deal. For now, we reiterate our fair value range (SEK2 – SEK24) with a base case valuation of SEK12.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera